Statement from IDSA President Thomas G. Slama, MD, FIDSA:
Congress took important action today against the public health threat of antibiotic resistance by passing the Food and Drug Administration Safety and Innovation Act (S 3187)* with provisions to address the lack of new antibiotics in development. The Act provides incentives to spur renewed interest in antibiotic research and development (R&D), to bring new antibiotics to the American people and provide ammunition against increasing drug resistance nationwide. It also calls for a review of antimicrobial stewardship programs as a critical tool for protecting the antibiotics we currently have against resistance, which can render them ineffective.
We are incredibly grateful to the bipartisan members of the House and Senate, including Reps. Phil Gingrey and Gene Green, and Sens. Richard Blumenthal and Bob Corker, for leading the charge in taking this important step in addressing this public health crisis.
While this was a critical first step, more work will be needed to ensure new antibiotics come to market, as outlined in IDSA’s 10 x ‘20 Initiative. We will continue to work with the other endorsers of the initiative to advocate for:
In addition to Congress, the American Medical Association’s (AMA) House of Delegates (HOD) also voiced its support of the development of critically needed new antibiotics as well as the protection of antibiotics once approved. The AMA HOD’s actions demonstrate organized medicine’s recognition of the vital importance of antibiotics, their uniqueness among medicines (i.e., they promote antibiotic resistance, which makes them less effective over time), and the need to create specialized mechanisms to both stimulate antibiotics’ development as well as protect their effectiveness for as long as possible. We commend the AMA HOD for recognizing that “the LPAD mechanism is an extremely promising potential tool for bringing high priority antibiotics to market” and acknowledging the importance of antimicrobial stewardship along with infection control programs “as critical components of assuring safe patient care.” To see the full resolutions, go to:
For more information about IDSA’s 10 x ’20 Initiative and other efforts to address antimicrobial resistance, visit www.AntibioticsNow.org.
* The Food and Drug Administration Safety and Innovation Act is a reconciled version of the Prescription Drug User Fee Act (PDUFA).
The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, prevention, and patient care. The Society, which has nearly 10,000 members, was founded in 1963 and is based in Arlington, VA. For more information, see www.idsociety.org.
1300 Wilson Boulevard | Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2013 Infectious Diseases Society of America